XORTX Therapeutics Inc. (XRTX) shareholders
XRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.10+0.18 (+19.57%)
Close on Nov 13, 2026Market cap $120.56KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0.6%
0M of 7M shares
Institutional holders
6
5 new, 1 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Lincoln Alternative Strategies LLC | 572,470 | 9.90% | 13G (passive) | Oct 23, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XRTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 23,116 | 0.33% | $52.47K | New | 0.00% |
| StoneX Group Inc. | 16,369 | 0.24% | $37.90K | New | 0.00% |
| Royal Bank of Canada | 732 | 0.01% | $2.00K | New | 0.00% |
| National Bank Of Canada /Fi/ | 162 | 0.00% | $329 | New | 0.00% |
| Clearstead Advisors, LLC | 55 | 0.00% | $120 | – | 0.00% |
| TD Waterhouse Canada Inc. | 9 | 0.00% | $19 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 6 | 0M | 0.6% | 5 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.0% | 2 / 0 | 0 / 0 | 0M | 0M |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
2.1
At 0M shares a day
Change since last report
-48.3%
From 0M shares
Short volume, 20 days
55.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of XORTX Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 309,426 shares on Oct 9, 2026 over the last 90 days.
See a number that looks wrong?